Glaucoma Trial, Recruiting NCT06139523 Sponsor: Duke University Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06139523
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 – Healthy adults:

  • Adults aged 18 or older who are willing and able to agree to take part in the study
  • People who are generally healthy with no known eye problems other than needing glasses or contact lenses
  • Women of childbearing age who complete a standard pregnancy screening evaluation before joining

Group 2 – Children:

  • Children under 18 years of age who are patients at Duke Eye Center, either as regular ophthalmology clinic patients or scheduled for a medically necessary eye examination under anaesthesia at Duke Eye Center
  • Cases where a healthcare provider familiar with the study agrees that the study team may contact the child's parent or legal guardian
  • Children whose parent or legal guardian is willing and able to give consent for their child to take part

Who may not be able to join:

Group 1 – Healthy adults:

  • People who are students or employees working directly under the supervision of the researchers running this trial
  • People who have previously had problems with eye drops that widen (dilate) the pupil
  • Women who are pregnant and would need to receive dilating eye drops as part of the study

Group 2 – Children:

  • Children whose parent or legal guardian is unwilling or unable to provide consent for participation
  • Children who have a health or eye condition that would prevent a standard eye examination or retinal imaging, such as cloudiness of the eye's lens or cornea (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (919)684-8434

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 January 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Presence of abnormal retinal microanatomy as measured by OCT reading; Severity of abnormal retinal microanatomy as measured by OCT reading; Retinal thickness at the fovea and surrounding optic nerve as measured by OCT analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov